Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas

Cancer

Volumn 85, Issue 3, 1999, Pages 669-677

  Shimizu, Motohiko ^a   Nikaido, Toshio ^a   Toki, Toshihiko ^a   Shiozawa, Tanri ^a   Fujii, Shingo ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Cell cycle regulatory molecules; Clear cell carcinoma; Ovarian adenocarcinoma; Prognostic factors

Indexed keywords

ADENOCARCINOMA; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, ENDOMETRIOID; CELL CYCLE PROTEINS; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; KI-67 ANTIGEN; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033083709     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F     Document Type: Article

References (38)

1. Scully RE. Tumors of the ovary and maldeveloped gonads. 2nd series. Washington, DC: Armed Forces Institute of Pathology, 1979:53-151.
2. Russel P. Surface epithelial-stromal tumors of the ovary. In: Kurman RJ. Blaustein's pathology of the female genital tract. 4th edition. New York: Springer-Verlag, 1994:705-82.
3. Toki T, Fujii S, Silverberg SG. A clinicopathologic study on the association of endometriosis and carcinoma of the ovary using a scoring system. Int J Gynecol Cancer 1996;6:68-75.
4. Jenison EL, Montag AG, Griffths CT, Welch WR, Lavin PT, Greer J, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
5. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage 3 disease. Gynecol Oncol 1996;60:412-7.
6. Aure JC, Høeg K, Kolstad P. Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Gynecol 1971;37:860-7.
7. Crozier MA, Copeland LJ, Silva EG, Gershenson DM, Stringer CA. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989;35:199-203.
8. Kitahara K, Yasui W, Kuniyasu H, Yokozaki H, Akama Y, Yunotani S, et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995;62: 25-8.
9. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 1996;93:15215-20.
10. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
11. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
12. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993;24:1175-9.
13. Kiyokawa T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression. Int J Gynecol Pathol 1994;13:311-8.
14. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53: 301-6.
15. Koshiyama M, Konishi I, Mandai M, Komatsu T, Yamamoto S, Nanbu K, et al. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas: correlation with clinicopathology and sex steroid receptor status. Virchows Arch 1995;425: 603-9.
16. Harlozinska A, Bar JK, Sedlaczek P, Gerber J. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms: correlation with histopathology. Am J Clin Pathol 1996;105: 334-40.
17. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, et al. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A in ovarian cancer is associated with progression and unfavorable prognosis. Int J Cancer 1997;74:57-63.
18. Werness BA, Jobe JS, DiCioccio RA, Piver MS. Expression of p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol 1997;16:149-55.
19. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A 1994; 91:11045-9.
20. Musgrove EA, Lilischkis R, Cornish AL, Lee CS, Setlur V, Seshadri R, et al. Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer 1995;63:584-91.
21. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
22. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-34.
23. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31:13-20.
24. Bertelsen K, Hølund B, Andersen E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer 1993;3:72-9.
25. Cattoretti G, Backer MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
26. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci U S A 1995;92:5386-90.
27. Rubin SC, Finstad CL, Federici MG, Schemer L, Lloyd KO, Hoskins WJ. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;73: 1456-9.
28. Skomedal H, Kristensen GB, Abeler VM, Borresen-Dale AL, Trope C, Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumors and stage 1 carcinoma. J Pathol 1997;181:158-65.
29. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 1992;151:237-44.
30. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GW. Wildtype p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1993;70:937-48.
31. Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H, et al. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer 1994;70:1191-7.
32. Sutherland RL, Watts CK, Musgrove EA. Cyclin gene expression and growth control in normal and neoplastic human breast epithelium. J Steroid Biochem Mol Biol 1993;47:99-106.
33. Shiozawa T, Lu X, Nikaido T, Fujii S. Immunohistochemical detection of cyclin A with reference to p53 expression in human uterine endometrioid carcinoma. Int J Gynecol Pathol 1997;16:348-53.
34. Yamamoto M, Yoshida M, Ono K, Fujita T, Ohtani-Fujita N, Sakai T, et al. Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34 cdc2 expression and normal p53 suppresses cyclin A expression. Exp Cell Res 1994;210:94-101.
35. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996;69:247-53.
36. Barboule N, Mazars P, Baldin V, Vidal S, Jozan S, Martel P, et al. Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995;63:611-5.
37. Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, et al. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Invest 1997;4:95-102.
38. Gamal HE, Jerome LB, Alexander WK, Charles VB, Graham C, Raymond RT, et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 1997;80:892-8.